Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Teladoc ( (TDOC) ) has provided an announcement.
On May 22, 2025, Teladoc Health, Inc. held its Annual Meeting of Stockholders, where several key proposals were approved. Notably, the stockholders approved an amendment to the 2023 Incentive Award Plan, increasing the number of shares available for issuance by 6,850,000. Additionally, the election of directors and the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, were confirmed. These decisions are expected to impact the company’s strategic direction and operational governance.
The most recent analyst rating on (TDOC) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Teladoc stock, see the TDOC Stock Forecast page.
Spark’s Take on TDOC Stock
According to Spark, TipRanks’ AI Analyst, TDOC is a Neutral.
Teladoc’s stock score reflects a mix of financial and operational challenges, including revenue fluctuations and negative profitability metrics, countered by strengths in cash flow and strategic acquisitions. Despite potential for growth in certain segments, bearish technical indicators and valuation concerns weigh heavily on the overall assessment.
To see Spark’s full report on TDOC stock, click here.
More about Teladoc
Teladoc Health, Inc. operates in the telehealth industry, providing virtual healthcare services and solutions. The company focuses on offering remote medical consultations and a range of digital health services to improve access to healthcare.
Average Trading Volume: 6,205,266
Technical Sentiment Signal: Strong Sell
Current Market Cap: $1.21B
For a thorough assessment of TDOC stock, go to TipRanks’ Stock Analysis page.